A RANDOMIZED PHASE II STUDY COMPARING IMATINIB AND THE COMBINATION OF IMATINIB AND PEGYLATED INTERFERON ALPHA-2B IN NEWLY DIAGNOSED NON-HIGH RISK CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE HEMATOLOGICAL REMISSION AFTER IMATINIB INDUCTION THERAPY

Trial Profile

A RANDOMIZED PHASE II STUDY COMPARING IMATINIB AND THE COMBINATION OF IMATINIB AND PEGYLATED INTERFERON ALPHA-2B IN NEWLY DIAGNOSED NON-HIGH RISK CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE HEMATOLOGICAL REMISSION AFTER IMATINIB INDUCTION THERAPY

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2011

At a glance

  • Drugs Imatinib; Peginterferon alfa-2b
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms Nordic IR-LR
  • Most Recent Events

    • 17 Jun 2011 Results published in Blood.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top